利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

14 条记录 (耗时 0.018 秒)

    METHODS FOR REDUCING THE RISK OF AN ADVERSE DRONEDARONE / CALCIUM CHANNEL BLOCKERS INTERACTION IN A PATIENT SUFFERING FROM ATRIAL FIBRILATION
    5.
    发明申请
    METHODS FOR REDUCING THE RISK OF AN ADVERSE DRONEDARONE / CALCIUM CHANNEL BLOCKERS INTERACTION IN A PATIENT SUFFERING FROM ATRIAL FIBRILATION 审中-公开
    降低患者从ATRIAL FIBRILATION引起的不良DRONEDARONE /钙通道阻断剂相互作用的风险的方法

    公开(公告)号：US20120005128A1

    公开(公告)日：2012-01-05

    申请号：US13172336

    申请日：2011-06-29

    申请人： Christine GAUD ,  Davide RADZIK

    发明人： Christine GAUD ,  Davide RADZIK

    IPC分类号： A61K31/343 ,  A61P9/06 ,  G06Q90/00 ,  A61P9/00

    CPC分类号： A61K31/40 ,  A61K31/277 ,  A61K31/343 ,  A61K31/554 ,  A61K45/06 ,  G06Q99/00 ,  A61K2300/00

    摘要： The disclosure relates to a method for managing the risk of dronedarone/calcium channel blockers interaction by using dronedarone or pharmaceutically acceptable salts thereof in patients with paroxysmal or persistent atrial fibrillation (AF) or atrial flutter (AFL), with a recent episode of AF/AFL and associated cardiovascular risk factors, who are in sinus rhythm or who will be cardioverted to reduce the risk of cardiovascular hospitalization, said patients also expecting to receive a calcium channel blockers treatment, by performing the following steps: a—initiate calcium channel blockers treatment at a low dose; b—performing a electrocardiogram (ECG) verification of good tolerability; c—increase of calcium channel blockers dose only if results in step b) are satisfying.

    摘要翻译： 本公开涉及一种通过在阵发性或持续性心房颤动（AF）或心房扑动（AFL）患者中使用决奈达隆或其药学上可接受的盐来控制决奈达隆/钙通道阻滞剂相互作用的风险的方法，最近一次AF / AFL和相关的心血管危险因素，谁是窦性心律或谁将被心脏转移降低心血管住院的风险，表示患者还期望接受钙通道阻滞剂治疗，通过执行以下步骤：a启动钙通道阻滞剂治疗 低剂量; b执行良好耐受性的心电图（ECG）验证; 仅当步骤b）中的结果令人满意时，钙通道阻滞剂的c-增加。

    METHODS FOR REDUCING THE RISK OF AN ADVERSE DRONEDARONE / BETA-BLOCKERS INTERACTION IN A PATIENT SUFFERING FROM ATRIAL FIBRILATION
    7.
    发明申请
    METHODS FOR REDUCING THE RISK OF AN ADVERSE DRONEDARONE / BETA-BLOCKERS INTERACTION IN A PATIENT SUFFERING FROM ATRIAL FIBRILATION 有权
    降低患者从ATRIAL FIBRILATION引起的不良DRONEDARONE / BETA-BLOCKERS相互作用风险的方法

    公开(公告)号：US20120000806A1

    公开(公告)日：2012-01-05

    申请号：US13172984

    申请日：2011-06-30

    申请人： Davide Radzik

    发明人： Davide Radzik

    IPC分类号： B65D90/48 ,  A61P9/00 ,  A61K31/343

    CPC分类号： A61K31/343

    摘要： The disclosure relates to a method for managing the risk of dronedarone/beta-blockers interaction by using dronedarone or pharmaceutically acceptable salts thereof in patients with paroxysmal or persistent atrial fibrillation (AF) or atrial flutter (AFL), with a recent episode of AF/AFL and associated cardiovascular risk factors, who are in sinus rhythm or who will be cardioverted to reduce the risk of cardiovascular hospitalization, said patients also expecting to receive a beta-blockers treatment, by performing the following steps: a—initiate beta-blockers treatment at a low dose; b—performing a electrocardiogram (ECG) verification of good tolerability; c—increase of beta-blockers dose only if results in step b) are satisfying.

    摘要翻译： 本公开涉及通过在阵发性或持续性房颤（AF）或心房扑动（AFL）患者中使用决奈达隆或其药学上可接受的盐来治疗决奈达隆/β-阻断剂相互作用的风险的方法，其中AF / AFL和相关的心血管危险因素，谁是窦性心律或谁将被心脏转移以降低心血管住院的风险，表示患者还期望通过执行以下步骤接受β受体阻滞剂治疗：a - 启动β-受体阻滞剂治疗 低剂量; b执行良好耐受性的心电图（ECG）验证; 仅当步骤b）中的结果令人满意时，β-阻断剂的c-增加。